A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ.
Helft PR, et al. Among authors: kindler hl.
Clin Cancer Res. 2004 Jul 1;10(13):4363-8. doi: 10.1158/1078-0432.CCR-04-0088.
Clin Cancer Res. 2004.
PMID: 15240523
Clinical Trial.